Roquefort Therapeutics (LON:COIL) Stock Price Up 2.9% – Time to Buy?

Roquefort Therapeutics plc (LON:COIL) shot up 2.9% during mid-day trading on Thursday . The stock traded as high as GBX 9 and last traded at GBX 9. 119,793 shares were traded during trading, a decline of 43% from the average session volume of 209,281 shares. The stock had previously closed at GBX 8.75.

Roquefort Therapeutics Trading Up 2.9%

The company has a market cap of £38.41 million, a P/E ratio of -0.41 and a beta of 0.05. The business’s 50-day moving average price is GBX 9.59 and its 200 day moving average price is GBX 9.61. The company has a debt-to-equity ratio of 8.18, a quick ratio of 3.07 and a current ratio of 0.63.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.